Kimberly Trotter

Kimberly Trotter

Auto-generated profile, based on publicly available information

Kimberly Trotter

Medicine, The University of Chicago, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2025 in Rheumatology
Verified
Journal Article
Closed access
JSJasvinder Singh
Jasvinder Singh
LHLarry R Hearld
Larry R Hearld
SESeth Eisen
Seth Eisen
WCW Winn Chatham
W Winn Chatham
SNSonali Narain
Sonali Narain
ICImplementing DEcision-Aid for Lupus in clinics (IDEAL) Consortium
Implementing DEcision-Aid for Lupus in clinics (IDEAL) Consortium
Objective: The objective of this study was to examine the clinical outcomes during the implementation of a self-administered patient decision-aid (PtDA) for lupus. Methods: We provided an effective computerized lupus PtDA in 15 rheumatology outpatient clinics 2019–2024 (including the COVID pandemic). We undertook Organizational Readiness to Implement Change Surveys (ORICs) and Team Learning and Psychological Safety Surveys (TLPSSs) at baseline. The primary study outcome objective measure, percent penetration/reach, was defined as the number of patients who viewed the lupus PtDA at the end of the study, divided by the total number of eligible patients (times 100). We used validated clinical personnel surveys to examine the perceived lupus PtDA appropriateness, acceptability, feasibility, success, and permanence, at 4 months, 12 months and 24 months post-PtDA implementation. Results: Among the sites, the clinical personnels’ (n = 184) baseline ORIC commitment and efficacy scores (a 0–5 scale, higher = better) ranged from 3.5 to 4.2, and 3.4 to 4.4, respectively; the TLPSS scores (a 0–7 scale, higher = better) were 3.9–5.5 for internal learning, 3.7–5.6 for external learning, and 4.3–5.5 for psychological safety. The penetration (primary outcome) among 15 geographically diverse US rheumatology clinics ranged from 3% to 44%. We found that the total number of providers in the clinic was positively associated with higher penetration. Clinical personnel–perceived lupus PtDA outcomes were optimal at 4 months (all scale scores ranged from 1 to 5, higher = better): (i) appropriateness, 3.43 (s.d. 0.86); (ii) acceptability, 3.53 (s.d. 0.83); (iii) feasibility, 3.44 (s.d. 0.71); (iv) success, 3.41 (s.d. 0.73); and (v) permanence, 3.22 (s.d. 0.74). Conclusion: We implemented a lupus PtDA with varied success rates during the COVID pandemic; more providers were associated with higher clinic penetration. Clinical personnel perceived high lupus PtDA appropriateness, acceptability, feasibility, success, and permanence that persisted up to 24 months. Trial Registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03735238.

26 May 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
TXTeresa Xiao
Teresa Xiao
AAAilia Ali
Ailia Ali
KTKimberly Trotter
Kimberly Trotter
A patient presented with fatigue, weight loss, haemoptysis, bullous rash and spiculated pulmonary nodules. Skin biopsy was consistent with Sweet’s syndrome (SS). Pertinent labs included a positive c- anti-neutrophil cytoplasmic antibody (ANCA) and positive proteinase 3 (PR3) antibody. Additional work-up included a lung biopsy which revealed multinucleated giant cells and repeat skin biopsy with small and medium vasculitis, leading to a diagnosis of granulomatosis with polyangiitis (GPA). SS is a neutrophilic dermatosis that often presents with malignancy, drugs or infection. SS has rarely been described in association with ANCA-vasculitis, with few reports of SS as a presenting symptom. Patients presenting with SS and additional features concerning for ANCA-vasculitis may benefit from further workup for vasculitis given the high morbidity and mortality associated with the disease.

22 October 2026 in Lupus
Verified
Journal Article
Open access
TXTeresa Xiao
Teresa Xiao
NPNatasha Powell
Natasha Powell
KTKimberly Trotter
Kimberly Trotter
KKKichul Ko
Kichul Ko
Objective: Pericarditis is a common and recurring manifestation of systemic lupus erythematosus (SLE). While guidelines for the management of SLE include the use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and glucocorticoids, the evidence for various treatments in SLE is limited. Evidence for the usage of colchicine for pericarditis in patients with SLE exists primarily in case reports and case series. The purpose of this study was to investigate colchicine usage and rates of recurrent pericarditis among patients with SLE. Methods: This retrospective cohort study included patients with SLE treated at a tertiary care center between 2015 and 2025. Patients were included if they presented to the hospital with pericarditis based on the 2025 European Society of Cardiology (ESC) Guidelines and had follow-up for at least 1 year. Based on the ESC guidelines, recurrent pericarditis was defined as new symptoms or disease activity after clinical remission and was captured within 1 year of the initial presentation. Results: Of the 55 patients included in the study, 47.3% received colchicine, 52.7% received NSAIDs and 56.4% received glucocorticoids. Recurrent pericarditis occurred in 45.5% of patients. In univariate analyses, age less than 40 years at first presentation of pericarditis was significantly associated with recurrent pericarditis as was treatment with an initiation or increase of glucocorticoids. Treatment with colchicine trended toward reduced recurrence, but the result was not statistically significant. In multivariate logistic regression including age, treatment with colchicine, and treatment with glucocorticoids, only treatment with glucocorticoids was significantly associated with recurrent pericarditis (odds ratio 4.31; 95% confidence interval 1.12-16.55). Conclusions: In this study, recurrent pericarditis was common among patients with SLE and was associated with treatment with glucocorticoids. Colchicine was associated with a trend toward decreased recurrence rates, but this was not statistically significant. Given high recurrence rates among patients treated with steroids, additional studies are needed on non-steroidal therapies for pericarditis in SLE, including further research on colchicine.

4 September 2024
Verified
Book Chapter
Closed access
PDF file
MMMichael Macklin
Michael Macklin
KTKimberly Trotter
Kimberly Trotter
Systemic lupus erythematosus (SLE) is a multisystem inflammatory autoimmune disease typically characterized by skin, joint, hematologic, and kidney involvement. The gastrointestinal manifestations are varied and often underrecognized by providers. SLE can additionally coexist with other gastrointestinal autoimmune disorders more commonly than in the general population. Specific manifestations of gastrointestinal disease in SLE may include intestinal pseudo-obstruction, esophageal motility, lupus peritonitis, lupus enteritis, protein-losing enteropathy, pancreatitis associated with SLE, lupus-associated acalculous cholecystitis, and lupus hepatitis. The severity of these conditions is highly variable and can mimic nonautoimmune gastrointestinal conditions, making their diagnosis challenging. This chapter serves as a dedicated review of gastrointestinal disease in SLE. <!----> <!----> <!----> <!---->